Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03948243 · ClinicalTrials.gov registry record · Phase 1
Licorice Botanical Dietary Supplements - Metabolism and Safety in Women
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03948243 is a Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 19 participants.
The verdict
NCT03948243, a Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Human safety studies will be carried out to test whether red clover botanical dietary supplements used by peri- and post-menopausal women are safe to use with Food and Drug Administration (FDA)-approved drugs. To test this, a red clover dietary supplement (previously tested in women at the University of Illinois at Chicago without any harmful effects) will be given with four selected FDA-approved drugs to determine if the Licorice supplement can increase or decrease how these medications are absorbed, metabolized and excreted by the human body. Preclinical studies predict that the licorice supplement might affect the metabolism or break down of these probe drugs.
Interventions
- DIETARY_SUPPLEMENT Licorice
- DRUG Alprazolam 2 MG
- DRUG Caffeine 100 MG
- DRUG Tolbutamide 250 mg
- DRUG Dextromethorphan 30mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03948243
The ClinicalTrials.gov registry entry for NCT03948243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Licorice is the first listed.
NCT03948243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03948243 about?
NCT03948243 is a clinical study titled "Licorice Botanical Dietary Supplements - Metabolism and Safety in Women". Human safety studies will be carried out to test whether red clover botanical dietary supplements used by peri- and post-menopausal women are safe to use with Food and Drug Administration (FDA)-approved drugs. To test this, a red clover dietary supplement (previously tested in women at the Universit...
What is the current status of trial NCT03948243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-04-01. Estimated completion is 2022-04-22.
What interventions are being tested in trial NCT03948243?
The interventions under investigation include: Licorice (DIETARY_SUPPLEMENT), Alprazolam 2 MG (DRUG), Caffeine 100 MG (DRUG), Tolbutamide 250 mg (DRUG), Dextromethorphan 30mg (DRUG).
Who is sponsoring clinical trial NCT03948243?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.